Iron Storage within Dopamine Neurovesicles Revealed by Chemical Nano-Imaging

Altered homeostasis of metal ions is suspected to play a critical role in neurodegeneration. However, the lack of analytical technique with sufficient spatial resolution prevents the investigation of metals distribution in neurons. An original experimental setup was developed to perform chemical element imaging with a 90 nm spatial resolution using synchrotron-based X-ray fluorescence. This unique spatial resolution, combined to a high brightness, enables chemical element imaging in subcellular compartments. We investigated the distribution of iron in dopamine producing neurons because iron-dopamine compounds are suspected to be formed but have yet never been observed in cells. The study shows that iron accumulates into dopamine neurovesicles. In addition, the inhibition of dopamine synthesis results in a decreased vesicular storage of iron. These results indicate a new physiological role for dopamine in iron buffering within normal dopamine producing cells. This system could be at fault in Parkinson's disease which is characterized by an increased level of iron in the substancia nigra pars compacta and an impaired storage of dopamine due to the disruption of vesicular trafficking. The re-distribution of highly reactive dopamine-iron complexes outside neurovesicles would result in an enhanced death of dopaminergic neurons.

[1]  R. Hider,et al.  The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy , 2005, British journal of pharmacology.

[2]  J. Connor,et al.  Iron, brain ageing and neurodegenerative disorders , 2004, Nature Reviews Neuroscience.

[3]  Diana Suffern,et al.  Photophysics of dopamine-modified quantum dots and effects on biological systems , 2006, Nature materials.

[4]  P. Moretto,et al.  Quantitative mapping of platinum and essential trace metal in cisplatin resistant and sensitive human ovarian adenocarcinoma cells. , 1996, Cellular and molecular biology.

[5]  P D Griffiths,et al.  Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. , 1999, Brain : a journal of neurology.

[6]  Anatoly Snigirev,et al.  Synchrotron hard x-ray microprobe: Fluorescence imaging of single cells , 2001 .

[7]  L. Greene,et al.  Morphologic and cytochemical properties of a clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. , 1978, Laboratory investigation; a journal of technical methods and pathology.

[8]  Patrik Brundin,et al.  Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein , 2002, Nature Reviews Neuroscience.

[9]  A. Torp,et al.  Fluorescence of catechol amines and related compounds condensed with formaldehyde , 1962, Brain Research Bulletin.

[10]  J. Segura-Aguilar,et al.  Dopamine-dependent iron toxicity in cells derived from rat hypothalamus. , 2005, Chemical Research in Toxicology.

[11]  L. Greene,et al.  Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[12]  C. Quintana,et al.  Study of the localization of iron, ferritin, and hemosiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. , 2006, Journal of structural biology.

[13]  A. Santagostino,et al.  Mitochondrial toxicity of iron and the protective role of ferritin on dopaminergic PC12 cell line. , 1995, Toxicology in vitro : an international journal published in association with BIBRA.

[14]  G. Deves,et al.  Microchemical element imaging of yeast and human cells using synchrotron X-ray microprobe with Kirkpatrick-Baez optics. , 2004, Analytical chemistry.

[15]  Subramanian Rajagopalan,et al.  Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo A Novel Therapy for Parkinson's Disease , 2003, Neuron.

[16]  J. Smythies The neurotoxicity of glutamate, dopamine, iron and reactive oxygen species: Functional interrelationships in health and disease: A review — discussion , 1999, Neurotoxicity Research.

[17]  S. Lipton,et al.  Molecular pathways to neurodegeneration , 2004, Nature Medicine.

[18]  A. Graybiel,et al.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.

[19]  V. M. Pickel,et al.  Preferential localization of a vesicular monoamine transporter to dense core vesicles in PC12 cells , 1994, The Journal of cell biology.

[20]  P. Cloetens,et al.  Efficient sub 100 nm focusing of hard x rays , 2005 .

[21]  V. A. Solé,et al.  A multiplatform code for the analysis of energy-dispersive X-ray fluorescence spectra , 2007 .

[22]  C. Marsden,et al.  INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAIN , 1987, The Lancet.

[23]  G. Thieme,et al.  FLUORESCENCE OF CATECHOL AMINES AND RELATED COMPOUNDS CONDENSED WITH FORMALDEHYDE , 1962 .

[24]  P. Kirkpatrick,et al.  Formation of optical images by X-rays. , 1948, Journal of the Optical Society of America.

[25]  M. Youdim,et al.  Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats , 2004, Neuropharmacology.

[26]  T. Rouault,et al.  Iron on the brain , 2001, Nature Genetics.

[27]  W. Linert,et al.  Redox reactions of neurotransmitters possibly involved in the progression of Parkinson's Disease. , 2000, Journal of inorganic biochemistry.

[28]  K. Zierold,et al.  The element distribution in ultrathin cryosections of cultivated fibroblast cells , 2004, Histochemistry.

[29]  J. Dankert,et al.  PENICILLIN-SENSITIVE STREPTOCOCCAL ENDOCARDITIS , 1982, The Lancet.

[30]  A. Kakita,et al.  Relationship Among &agr;-Synuclein Accumulation, Dopamine Synthesis, and Neurodegeneration in Parkinson Disease Substantia Nigra , 2006, Journal of neuropathology and experimental neurology.

[31]  Y. Agid,et al.  Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson's disease , 1993, Brain Research.

[32]  Peter Riederer,et al.  Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.

[33]  H. Lashuel,et al.  Rescuing defective vesicular trafficking protects against alpha-synuclein toxicity in cellular and animal models of Parkinson's disease. , 2006, ACS chemical biology.

[34]  D. Eide Zinc transporters and the cellular trafficking of zinc. , 2006, Biochimica et biophysica acta.

[35]  Ya Ke,et al.  Iron misregulation in the brain: a primary cause of neurodegenerative disorders , 2003, The Lancet Neurology.

[36]  D. Smith,et al.  Manganese oxidation state mediates toxicity in PC12 cells. , 2005, Toxicology and applied pharmacology.

[37]  Sriram Subramaniam,et al.  Electron tomography of degenerating neurons in mice with abnormal regulation of iron metabolism. , 2005, Journal of structural biology.